RVMD daraxonrasib Phase 3 trial results

On May 1, 2026, Revolution Medicines (RVMD) received a "safe to proceed" letter from the FDA for its Phase 3 trial of daraxonrasib, a pancreatic cancer treatment. This news, coupled with stellar trial results announced on April 13, drove RVMD's stock to an all-time high, making it one of the best performing healthcare stocks and top gainers in 2026.

The biotech sector, particularly pancreatic cancer drug development, has been significantly impacted. RVMD's shares soared, breaking above key moving averages, and investors cheered the unprecedented survival rates demonstrated by daraxonrasib. The positive trial results have also boosted confidence in Revolution Medicines' pipeline and its potential to disrupt the pancreatic cancer treatment landscape.

Investors should now watch for the completion of the Phase 3 trial (expected in Q4 2026) and the FDA's decision on daraxonrasib's accelerated approval, which is anticipated in early 2027. Additionally, Revolution Medicines' upcoming Q2 2026 earnings report (scheduled for August 15) will provide insights into the company's financial health and potential future developments.